L'hospitalet De Llobregat

• A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppressio … Recruiting
  2023-506879-98-00 6 2024-01-22 Renal transplantation
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: randomized clinical trial. Study 1: Immediate Kidne … Recruiting
  2023-506437-29-00 5 2023-12-19 Preventive treatment of post-kidney transplant diabetes
• FOENIX-CCA4 Recruiting
  2023-503665-39-00 4 2023-11-14 Advanced cholangiocarcinoma
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting
  2023-505385-28-00 4 2023-10-19 male or pre/post-menopausal women age ≥ 18 years with locally advanced
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of elacestran … Recruiting
  2023-503373-37-01 4 2023-09-11 Premenopausal women with early luminal breast cancer
• A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting
  2022-502755-59-00 1 2023-08-30 Locally Advanced or Metastatic Solid Tumors with FGFR3 Alterations
• A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or … Recruiting
  2022-501508-82-00 3 2023-08-23 Solid Tumors
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor i … Recruiting
  2023-504709-35-00 1 2023-08-16 Locally advanced or metastatic solid tumors
• First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion study Recruiting
  2022-502645-99-00 7 2023-08-09 MTAP-deleted Advanced or Metastatic Solid Tumors
• Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA … Recruiting
  2024-519194-19-00 7 2023-06-06 Chronic lymphocytic leukemia (CLL)
• Master protocol of novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction … Recruiting
  2024-510977-27-00 4 2023-04-14 Locally Advanced Unresectable or Metastatic Gastric or Gastroesophagea
• Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence … Recruiting
  2024-517666-41-00 5 2023-03-13 Prostate Cancer
• Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting
  2023-507233-19-00 10 2023-02-16 Treatment of IgAN
• A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid … Recruiting
  2023-505065-91-00 4 2023-01-30 Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
• Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting
  2023-507041-28-00 4 2022-11-28 Solid and Hematological Malignancies
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital

Showing 409–432 of 1,017 trials